The First Generic EpiPen Just Received FDA Approval

iStock
iStock

For people with severe allergies, having an EpiPen on hand could mean the difference between life and death. But that safety net comes at a high price: In the past decade, the cost of the brand-name drug has risen by more than 400 percent, with a set of two pens selling for $600. Now, CNBC reports that patients can finally get the treatment they need for a more reasonable amount of cash: The FDA has approved a generic version of Mylan's EpiPen, making it the first direct generic competitor to the brand-name medication.

Teva Pharmaceutical's versions of both the EpiPen and EpiPen Jr. will work like the originals, with an injector delivering epinephrine, a chemical that opens the airways, into the bloodstream of someone suffering an allergic reaction. Similar generics have been made commercially available in the past: In 2016, Mylan introduced a cheaper version of its own product at $300 for a two-pack, and in 2017 CVS started selling an EpiPen alternative for $110. Teva's drug is different, though. It's a direct generic copy of the EpiPen, which means pharmacists will be free to offer it to patients who have been prescribed Mylan's product. A price hasn't been announced, but Teva's EpiPen could end up being significantly cheaper than Mylan's generic EpiPen, which could in turn bring down prices of the injector drug across the board.

The exorbitant price of the EpiPen has hit patients hard in recent years. Some EMTs have even started loading epinephrine into syringes manually rather than paying for the drug-injector combo. Though the drug itself isn't protected by a patent, the design of the EpiPen device is difficult for competing pharmaceutical companies to replicate, which has allowed Mylan to charge whatever it can for the product.

In 2017, the FDA tweaked its guidelines to make it easier for generic EpiPen competitors to receive market approval, even if the design of the new injector differed slightly from the original. With the approval of Teva's auto-injector made official, more EpiPen generics could soon start appearing behind pharmacy counters.

[h/t CNBC]

Crocs Is Donating More Than 100,000 Pairs of Shoes to Healthcare Workers

Sturdy, comfortable Crocs are a favorite among healthcare professionals.
Sturdy, comfortable Crocs are a favorite among healthcare professionals.
David Silverman/Getty Images

Crocs have long been a favorite among healthcare workers who spend hours on their feet each day—and now, they can get a pair for free.

This week, the company announced that it will give away more than 100,000 pairs of shoes to medical professionals fighting the new coronavirus in the U.S. ClickOrlando reports that workers can submit their requests for Crocs Classic Clogs or Crocs at Work via an online form on the Crocs website, which will open each weekday at 12 p.m. EST and continue accepting orders until it fulfills its daily allotment.

According to a press release, that allotment is a whopping 10,000 pairs of shoes per day. The as-yet-unspecified end date for the program—called “A Free Pair for Healthcare”—depends on inventory levels and the number of requests the company receives. In addition to shipping shoes to individuals, Crocs is also planning to donate up to 100,000 more pairs directly to healthcare organizations. So far, they’ll send shoes to the Dayton Area Hospital Association in Ohio, St. Anthony North Health Campus in Denver, Colorado, the Atlantic Health System in New Jersey, and more.

“These workers have our deepest respect, and we are humbled to be able to answer their call and provide whatever we can to help during this unprecedented time,” Crocs president and CEO Andrew Rees said in the release. “Share the word to all those in healthcare and please be mindful to allow those who need these most to place their requests. This is the least we can do for those working incredibly hard to defeat this virus.”

Healthcare professionals can request their free Crocs here.

[h/t ClickOrlando]

On This Day in 1953, Jonas Salk Announced His Polio Vaccine

Getty Images
Getty Images

On March 26, 1953, Dr. Jonas Salk went on CBS radio to announce his vaccine for poliomyelitis. He had worked for three years to develop the polio vaccine, attacking a disease that killed 3000 Americans in 1952 alone, along with 58,000 newly reported cases. Polio was a scourge, and had been infecting humans around the world for millennia. Salk's vaccine was the first practical way to fight it, and it worked—polio was officially eliminated in the U.S. in 1979.

Salk's method was to kill various strains of the polio virus, then inject them into a patient. The patient's own immune system would then develop antibodies to the dead virus, preventing future infection by live viruses. Salk's first test subjects were patients who had already had polio ... and then himself and his family. His research was funded by grants, which prompted him to give away the vaccine after it was fully tested.

Clinical trials of Salk's vaccine began in 1954. By 1955 the trials proved it was both safe and effective, and mass vaccinations of American schoolchildren followed. The result was an immediate reduction in new cases. Salk became a celebrity because his vaccine saved so many lives so quickly.

Salk's vaccine required a shot. In 1962, Dr. Albert Sabin unveiled an oral vaccine using attenuated (weakened but not killed) polio virus. Sabin's vaccine was hard to test in America in the late 1950s, because so many people had been inoculated using the Salk vaccine. (Sabin did much of his testing in the Soviet Union.) Oral polio vaccine, whether with attenuated or dead virus, is still the preferred method of vaccination today. Polio isn't entirely eradicated around the world, though we're very close.

Here's a vintage newsreel from the mid 1950s telling the story:

For more information on Dr. Jonas Salk and his work, click here.

SECTIONS

arrow
LIVE SMARTER